Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.37
-0.08-3.27%
At close: -
$2.37
0.000.00%
After Hours: 4:02 PM EDT
Comments
Loading...
Kyverna Therapeutics Analyst Ratings and Price Targets | NASDAQ:KYTX | Benzinga
Kyverna Therapeutics Inc has a consensus price target of $23.2 based on the ratings of 5 analysts. The high is $40 issued by Morgan Stanley on March 4, 2024. The low is $6 issued by HC Wainwright & Co. on November 20, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Wells Fargo, and UBS on November 20, 2024, November 15, 2024, and October 10, 2024, respectively. With an average price target of $14.33 between HC Wainwright & Co., Wells Fargo, and UBS, there's an implied 504.78% upside for Kyverna Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wells Fargo
UBS
JP Morgan
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Kyverna Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/20/2024 | Buy Now | 153.16% | HC Wainwright & Co. | Mitchell Kapoor45% | $7 → $6 | Maintains | Neutral | Get Alert |
| 11/15/2024 | Buy Now | 912.66% | Wells Fargo | Derek Archila59% | $44 → $24 | Maintains | Overweight | Get Alert |
| 10/10/2024 | Buy Now | 448.52% | UBS | Trung Huynh69% | → $13 | Initiates | → Buy | Get Alert |
| 09/19/2024 | Buy Now | 195.36% | HC Wainwright & Co. | Mitchell Kapoor45% | $7 → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 08/15/2024 | Buy Now | 195.36% | HC Wainwright & Co. | Mitchell Kapoor45% | $8 → $7 | Maintains | Neutral | Get Alert |
| 07/31/2024 | Buy Now | 1292.41% | JP Morgan | Brian Cheng38% | $39 → $33 | Maintains | Overweight | Get Alert |
| 07/16/2024 | Buy Now | 237.55% | HC Wainwright & Co. | Mitchell Kapoor45% | $8 → $8 | Reiterates | Neutral → Neutral | Get Alert |
| 07/03/2024 | Buy Now | 237.55% | HC Wainwright & Co. | Mitchell Kapoor45% | → $8 | Initiates | → Neutral | Get Alert |
| 03/04/2024 | Buy Now | 1545.57% | JP Morgan | Brian Cheng38% | → $39 | Initiates | → Overweight | Get Alert |
| 03/04/2024 | Buy Now | 1587.76% | Morgan Stanley | Michael Ulz58% | → $40 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Kyverna Therapeutics (KYTX) stock?
The latest price target for Kyverna Therapeutics (NASDAQ:KYTX) was reported by HC Wainwright & Co. on November 20, 2024. The analyst firm set a price target for $6.00 expecting KYTX to rise to within 12 months (a possible 153.16% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kyverna Therapeutics (KYTX)?
The latest analyst rating for Kyverna Therapeutics (NASDAQ:KYTX) was provided by HC Wainwright & Co., and Kyverna Therapeutics maintained their neutral rating.
When was the last upgrade for Kyverna Therapeutics (KYTX)?
There is no last upgrade for Kyverna Therapeutics
When was the last downgrade for Kyverna Therapeutics (KYTX)?
There is no last downgrade for Kyverna Therapeutics.
When is the next analyst rating going to be posted or updated for Kyverna Therapeutics (KYTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kyverna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kyverna Therapeutics was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.
Is the Analyst Rating Kyverna Therapeutics (KYTX) correct?
While ratings are subjective and will change, the latest Kyverna Therapeutics (KYTX) rating was a maintained with a price target of $7.00 to $6.00. The current price Kyverna Therapeutics (KYTX) is trading at is $2.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.